Business
Everest Medicines Announces NMPA Approval of IND Application for Tumor-Associated Antigen Cancer Vaccine EVM14
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the Investigational New Drug (IND) application for EVM14, a Tumor-Associated Antigen (TAA) cancer vaccine, has been approved by the National Medical Products Administration (NMPA) in China. This achievement marks a key milestone in the Company's efforts to develop innovative mRNA
About this update from Everest Medicines Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"EVM14 becomes Everest Medicines' internally developed therapeutic mRNA cancer vaccine to receive IND approvals from both China's National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA).","length":233,"tagName":"p"}]},{"val":[{"type":"text","content":"EVM14, an off-the-shelf therapeutic mRNA cancer vaccine, is developed based on Everest Medicines' proprietary mRNA platform. It is formulated with mRNA encoding 5 tumor-associated antigens (TAAs) and is designed to treat various squamous cell carcinomas.","length":263,"tagName":"p"}]},{"val":[{"type":"text","content":"In preclinical studies, EVM14 demonstrated the ability to induce immune memory and prevent tumor recurrence, offering hope for long-term cancer-free survival.","length":158,"tagName":"p"}]},{"val":[{"type":"text","content":"Tumor-associated antigen vaccines offer distinct advantages, including elimination of HLA screening requirements, off-the-shelf availability, lower production costs versus personalized neoantigen vaccines, and applicability across multiple tumor types.","length":257,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":911,"olType":false},{"type":"text","content":"SHANGHAI, Oct. 13, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the Investigational New Drug (IND) application for EVM14, a Tumor-Associated Antigen (TAA) cancer vaccine, has been approved by the National Medical Products Administration (NMPA) in China. This achievement marks a key milestone in the Company's efforts to develop innovative mRNA therapeutics in oncology. EVM14 becomes Everest Medicines' internally developed therapeutic mRNA cancer vaccine to receive IND approvals from both China's National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA).","length":829,"tagName":"p"},{"type":"text","content":"EVM14, an off-the-shelf therapeutic mRNA cancer vaccine, is developed based on Everest Medicines' proprietary mRNA platform. It is formulated with mRNA encoding 5 tumor-associated antigens (TAAs) and is designed to tr...